Skip to main content
Figure 1 | Molecular Neurodegeneration

Figure 1

From: Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease

Figure 1

Plasma and brain pharmacokinetics of dimebon following acute on chronic dosing in wild type mice. (A) Plasma pharmacokinetic profile of dimebon following acute on chronic dosing of dimebon (12 mg/kg BW) over 6 hours, right panel: LC-MS separation of dimebon detected in extracts of plasma (B) Brain pharmacokinetic profile of dimebon following acute on chronic dosing of dimebon (12 mg/kg BW), right panel: representative LC-MS separation of dimebon detected in extracts of mouse brain tissues. Data represents mean ± SD n = 3 mice per group.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326